Key Takeaway: Recent developments in the U.S. and China highlight that strong patent strategy and IP risk management are critical for companies operating in the solar supply chain. In March…
In this episode of Knobbe IP+, Knobbe Martens’ ITC Litigation Co-Chairs Jonathan Bachand and Sheila Swaroop answer some of the most asked questions about IP enforcement and Section 337 investigations…
Johnson & Johnson (J&J) reported on April 24, 2026, that it has entered into an agreement to acquire Atraverse Medical, a company in the cardiovascular medical device sector, for an undisclosed amount. The deal…
Key Takeaways: eVTOL aircraft are moving toward real-world deployment, but certification remains a critical hurdle alongside early operational programs like the FAA’s eIPP. As companies advance in parallel, careful coordination…
Recently, Drummond Scientific Company announced its acquisition of Accu-Glass. Drummond, headquartered near Philadelphia, has more than 75 years of experience in precision manufacturing for the life sciences and medical technology industries, including the manufacture of medical…
Key Takeaways: Technological advancements in geothermal exploration and drilling are reducing uncertainty and lowering risk profiles, making private investors and lenders more willing to commit capital that was historically constrained…
Key Takeaway: Genetically engineered cultured host cells containing recombinant nucleic acids useful for gene therapy are patent-eligible for being markedly different from anything occurring in nature. In REGENXBIO Inc. v….
Key Takeaways: The domestic battery race is being won by companies, such as NOVONIX, that are developing innovative IP and meeting critical operational and/or commercial milestones based on that IP….
The U.S. Food and Drug Administration (FDA) has increasingly emphasized the use of real-world evidence (RWE) to support regulatory decision-making for medical devices. As medical technologies evolve and data sources…
On April 23, 2026, the Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA) announced “a new pathway designed to expedite access to certain FDA-designated Class II…
